Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phibro Animal Health (PAHC) Cash & Equivalents (2016 - 2026)

Phibro Animal Health has reported Cash & Equivalents over the past 13 years, most recently at $55.5 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 17.28% year-over-year to $55.5 million; the TTM value through Dec 2025 reached $55.5 million, down 17.28%, while the annual FY2025 figure was $68.0 million, 3.65% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $55.5 million at Phibro Animal Health, down from $72.8 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $76.3 million in Q3 2022 and troughed at $33.0 million in Q4 2023.
  • A 5-year average of $57.2 million and a median of $57.9 million in 2025 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: crashed 51.81% in 2023 and later surged 103.44% in 2024.
  • Year by year, Cash & Equivalents stood at $63.4 million in 2021, then grew by 7.95% to $68.4 million in 2022, then crashed by 51.81% to $33.0 million in 2023, then surged by 103.44% to $67.1 million in 2024, then dropped by 17.28% to $55.5 million in 2025.
  • Business Quant data shows Cash & Equivalents for PAHC at $55.5 million in Q4 2025, $72.8 million in Q3 2025, and $68.0 million in Q2 2025.